APA

Vanrenterghem Y., Bresnahan B., Campistol J., Durrbach A., Grinyó J., Neumayer H., Lang P., Larsen C. P., Mancilla-Urrea E., Pestana J. M., Block A., Duan T., Glicklich A., Gujrathi S. & Vincenti F. (20110701). Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). : Transplantation.

Chicago

Vanrenterghem Yves, Bresnahan Barbara, Campistol Josep, Durrbach Antoine, Grinyó Josep, Neumayer Hans-Hellmut, Lang Philippe, Larsen Christian P, Mancilla-Urrea Eduardo, Pestana José Medina, Block Alan, Duan Tao, Glicklich Alan, Gujrathi Sheila and Vincenti Flavio. 20110701. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). : Transplantation.

Harvard

Vanrenterghem Y., Bresnahan B., Campistol J., Durrbach A., Grinyó J., Neumayer H., Lang P., Larsen C. P., Mancilla-Urrea E., Pestana J. M., Block A., Duan T., Glicklich A., Gujrathi S. and Vincenti F. (20110701). Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). : Transplantation.

MLA

Vanrenterghem Yves, Bresnahan Barbara, Campistol Josep, Durrbach Antoine, Grinyó Josep, Neumayer Hans-Hellmut, Lang Philippe, Larsen Christian P, Mancilla-Urrea Eduardo, Pestana José Medina, Block Alan, Duan Tao, Glicklich Alan, Gujrathi Sheila and Vincenti Flavio. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). : Transplantation. 20110701.